Regeneron’s Ronapreve Antibody Cocktail (casirivimab and imdevimab) Receives MHLW’s Approval for the Treatment of Mild to Moderate COVID-19

July 20, 2021 Auto Bot approval, Casirivimab, Imdevimab, MHLW, Regeneron, regulatory 0

Shots:

  • The approval is based on the results from a P-III trial evaluating Ronapreve (casirivimab and imdevimab) in high-risk non-hospitalized patients with COVID-19
  • The results showed a reduction in the risk of hospitalization or death by 70% in addition to the results from a P-I trial that demonstrated the safety, tolerability & PK in Japanese patients
  • This marks the first time the Ab cocktail, known as REGEN-COV in the US and Ronapreve in other countries, has received a full approval to treat COVID-19

Click here ­to­ read full press release/ article | Ref:  Prnewswire | Image: Fierce Pharma

The post Regeneron’s Ronapreve Antibody Cocktail (casirivimab and imdevimab) Receives MHLW’s Approval for the Treatment of Mild to Moderate COVID-19 first appeared on PharmaShots.